# Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

- Source: PR Newswire
- Published: 2026-10-26T09:18:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/innovent-announces-nmpa-acceptance-of-a-new-indication-application-of-sintilimab-for-the-treatment-of-advanced-melanoma-302919197.html
- Canonical: https://groundlevelnews.com/story/innovent-announces-nmpa-acceptance-of-a-new-indication-application-of--0c5a51/

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._